REFERENCES
- UKCCSG NHL Group. Guidelines for the management of Burkitt/Burkitt-like and large B cell non-Hodgkin lymphoma. B cell NHL treatment recommendations, , et al. United Kingdom Childrens Cancer Study Group, July 2003
- Jaffe ES, Harris NL, Stein H, et al. Tumours of Haematopoietic and Lymphoid Tissues: World Health Organisation Classification of Tumours; Pathology and Genetics. IARC, Lyon 2001
- Kaleem Z. Flow cytometric analysis of lymphomas: current status and usefulness. Arch Pathol Lab Med. 2006; 130: 1850–1858
- Hanson CA, Kurtin PJ, Katzmann JA, et al. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood. 1999; 94: 3889–3896
- Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogenic transplantation for high risk malignant lymphoma. Ann Oncol. 1999; 10: 527–532
- Wang EH, Chen YA, Corringham S, et al. High dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004; 34: 581–587
- Nagano M, Kimura N, Akiyoshi T, et al. T-stem cell leukemia/lymphoma with both myeloid lineage conversion and T-specific delta recombination. Leuk Res 1997; 21: 767–773
- Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369: 1947–1954